Keros Therapeutics, Inc. (KROS) — Operating Income
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | $67.57M | +132.0% |
| 2024 | -$210.83M | -24.1% |
| 2023 | -$169.94M | -48.0% |
| 2022 | -$114.79M | -103.6% |
| 2021 | -$56.37M | -20.8% |
| 2020 | -$46.66M | -341.7% |
| 2019 | -$10.56M | — |
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | $67.57M | +132.0% |
| 2024 | -$210.83M | -24.1% |
| 2023 | -$169.94M | -48.0% |
| 2022 | -$114.79M | -103.6% |
| 2021 | -$56.37M | -20.8% |
| 2020 | -$46.66M | -341.7% |
| 2019 | -$10.56M | — |